TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing the Transmission of Influenza by Face Masks
Brief Summary: Pharmaceutical interventions, particularly vaccination, have been the principal public health method of preventing and controlling seasonal influenza. Other less invasive non-pharmaceutical interventions include the use of face masks and hand hygiene. In Asia, masks are used extensively, especially in Japan, but with only circumstantial evidence of efficacy. Although there are numerous studies that support hand hygiene as an effective measure for decreasing transmission of enteric infections, there are fewer data assessing the effect of hand hygiene on respiratory illnesses. Therefore it is proposed that a study be conducted on the use of face masks with and without the use of hand hygiene in comparison to no intervention in residence housing units of the University of Michigan. The interventions will be carried out during a period of influenza transmission that is defined by surveillance conducted at the University Health Service. Data will be collected on use of the interventions and the occurrence of influenza and other illnesses. When illness occurs meeting a case definition, specimens for viral isolation will be collected in all intervention settings. Face masks could theoretically lead to a large reduction in transmission frequency of influenza, especially if most transmission occurs by the airborne (large or small droplet) route. Even a modest reduction could have a major effect during an influenza pandemic.


Options:
A: Intervention Type: PROCEDURE; Name: Laparotomy+ HIPEC +/- CRS; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Face mask | Intervention Type: DEVICE; Name: control; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Face mask; Assigned to Arm(s): 1
C: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
D: Arm Label: Green tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea | Arm Label: water; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: green tea | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea; Assigned to Arm(s): Green tea, water

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing the Transmission of Influenza by Face Masks
Brief Summary: Pharmaceutical interventions, particularly vaccination, have been the principal public health method of preventing and controlling seasonal influenza. Other less invasive non-pharmaceutical interventions include the use of face masks and hand hygiene. In Asia, masks are used extensively, especially in Japan, but with only circumstantial evidence of efficacy. Although there are numerous studies that support hand hygiene as an effective measure for decreasing transmission of enteric infections, there are fewer data assessing the effect of hand hygiene on respiratory illnesses. Therefore it is proposed that a study be conducted on the use of face masks with and without the use of hand hygiene in comparison to no intervention in residence housing units of the University of Michigan. The interventions will be carried out during a period of influenza transmission that is defined by surveillance conducted at the University Health Service. Data will be collected on use of the interventions and the occurrence of influenza and other illnesses. When illness occurs meeting a case definition, specimens for viral isolation will be collected in all intervention settings. Face masks could theoretically lead to a large reduction in transmission frequency of influenza, especially if most transmission occurs by the airborne (large or small droplet) route. Even a modest reduction could have a major effect during an influenza pandemic.


Options:
A: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
B: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
C: Arm Label: Symptom tracker users; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Symptom tracker users
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Soap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soap; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing the Transmission of Influenza by Face Masks
Brief Summary: Pharmaceutical interventions, particularly vaccination, have been the principal public health method of preventing and controlling seasonal influenza. Other less invasive non-pharmaceutical interventions include the use of face masks and hand hygiene. In Asia, masks are used extensively, especially in Japan, but with only circumstantial evidence of efficacy. Although there are numerous studies that support hand hygiene as an effective measure for decreasing transmission of enteric infections, there are fewer data assessing the effect of hand hygiene on respiratory illnesses. Therefore it is proposed that a study be conducted on the use of face masks with and without the use of hand hygiene in comparison to no intervention in residence housing units of the University of Michigan. The interventions will be carried out during a period of influenza transmission that is defined by surveillance conducted at the University Health Service. Data will be collected on use of the interventions and the occurrence of influenza and other illnesses. When illness occurs meeting a case definition, specimens for viral isolation will be collected in all intervention settings. Face masks could theoretically lead to a large reduction in transmission frequency of influenza, especially if most transmission occurs by the airborne (large or small droplet) route. Even a modest reduction could have a major effect during an influenza pandemic.


Options:
A: Arm Label: 1. Surgical; Type: ACTIVE_COMPARATOR; Interventions: Device: Surgical mask | Arm Label: 2. N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 mask | Intervention Type: DEVICE; Name: Surgical mask; Assigned to Arm(s): 1. Surgical | Intervention Type: DEVICE; Name: N95 mask; Assigned to Arm(s): 2. N95 Respirator
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Alcohol-based hand sanitizer & quaternary ammonium wipes | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alcohol-based hand sanitizer & quaternary ammonium wipes; Assigned to Arm(s): 1
C: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
D: Intervention Type: PROCEDURE; Name: Laparotomy+ HIPEC +/- CRS; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Everolimus (RAD001); Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus (RAD001)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 0.1 % Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Arm Label: 1% Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 0.1 % Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 1% Rapamycin
D: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.


Options:
A: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
D: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin in the Treatment of Autism
Brief Summary: The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
B: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
C: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin in the Treatment of Autism
Brief Summary: The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.


Options:
A: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin in the Treatment of Autism
Brief Summary: The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
C: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Hydrocortisone on Humoral and Cellular Immunologic Markers in High Risk Patients After Cardiac Surgery
Brief Summary: Hydrocortisone has been shown to improve the early outcome of high risk patients after cardiac surgery. A potential mechanism resulting in this effect may be its immunomodulatory action. In this prospective interventional study this hypothesis is to be proven.


Options:
A: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline
B: Arm Label: Methylprednisolone Arm; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic saline | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone Arm | Intervention Type: DRUG; Name: Isotonic saline; Assigned to Arm(s): Placebo Arm
C: Arm Label: Single dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (IVMP) | Arm Label: Two Dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (two doses IVMP) | Intervention Type: DRUG; Name: methylprednisolone (IVMP); Assigned to Arm(s): Single dose steroid | Intervention Type: DRUG; Name: methylprednisolone (two doses IVMP); Assigned to Arm(s): Two Dose steroid
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): A, B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain
Brief Summary: The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic low back pain. The double-blind treatment intervention duration is 12 weeks, during which time supplemental analgesic medication (immediate-release oxycodone for the first 6 days post-randomization and acetaminophen or ibuprofen for the remainder of the double-blind phase) will be provided to all subjects in addition to study drug.


Options:
A: Intervention Type: DRUG; Name: CG 5503;tapentadol; Assigned to Arm(s): N/A
B: Arm Label: Double-blind BTDS 10 or 20; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine transdermal system | Arm Label: Double-blind Placebo TDS; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buprenorphine transdermal system; Assigned to Arm(s): Double-blind BTDS 10 or 20 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo TDS
C: Intervention Type: DRUG; Name: Oxymorphone Extended Release; Assigned to Arm(s): N/A
D: Arm Label: OROS hydromorphone; Type: EXPERIMENTAL; Interventions: Drug: OROS hydromorphone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: OROS hydromorphone; Assigned to Arm(s): OROS hydromorphone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction
Brief Summary: Patients in cardiogenic shock complicating acute myocardial infarction (AMI) are referred to a tertiary care center for percutaneous coronary intervention (PCI) of the infarct related artery in this multicenter, ran-domized clinical trial. After checking in- and exclusion criteria computerized randomization is performed to either PCI plus intraaortic balloon pump (IABP) insertion and medical treatment or PCI plus medical treatment only. Intensive care treatment is performed according to standard care including hemodynamic monitoring using a pulmonary artery catheter for optimal volume status adaptation and inotropic drug administration.

The IABP will be weaned after hemodynamic stabilization. Primary outcome measure will be 30-day mortality. The secondary outcome measures such as hemody-namic, laboratory and clinical parameters will serve as surrogate for prognosis of the patients.


Options:
A: Arm Label: Intraaortic balloon pump; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic balloon pump | Arm Label: No intraaortic balloon pump; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Intraaortic balloon pump; Assigned to Arm(s): Intraaortic balloon pump
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: levosimendan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo,; Assigned to Arm(s): 2
C: Arm Label: Losartan; Type: EXPERIMENTAL; Interventions: Drug: Losartan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DEVICE; Name: Intra-aortic balloon pump counterpulsation; Assigned to Arm(s): N/A

Answer: A